Edition:
United Kingdom

Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

62.16USD
7:50pm BST
Change (% chg)

$0.35 (+0.57%)
Prev Close
$61.81
Open
$60.81
Day's High
$63.24
Day's Low
$60.81
Volume
40,738
Avg. Vol
133,148
52-wk High
$65.55
52-wk Low
$29.17

Latest Key Developments (Source: Significant Developments)

Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study
Wednesday, 8 May 2019 

May 7 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ANNOUNCES EXPANDED SAFETY AND PRELIMINARY PREVENTIVE EFFICACY DATA FROM ONGOING LONG-TERM SAFETY STUDY, AND PRESENTS CASE REPORTS OF USING RIMEGEPANT TO SUCCESSFULLY TREAT BREAKTHROUGH MIGRAINE ATTACKS IN PATIENTS TAKING PREVENTIVE CGRP-TARGETING MONOCLONAL ANTIBODIES.BIOHAVEN - BASED ON INTERIM ANALYSIS OF STUDY BHV3000-201, RIMEGEPANT WAS WELL TOLERATED WITH LONG-TERM DOSING UP TO ONE YEAR IN PATIENTS WITH MIGRAINE.  Full Article

Biohaven Pharmaceutical Holding Company Q1 Loss Per Share $1.41
Tuesday, 7 May 2019 

Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND ADVANCEMENTS IN NEUROINNOVATION PLATFORMS.Q1 LOSS PER SHARE $1.41.Q1 EARNINGS PER SHARE ESTIMATE $-1.48 -- REFINITIV IBES DATA.  Full Article

Biohaven's Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN'S VERDIPERSTAT RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR MULTIPLE SYSTEM ATROPHY.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD - REMAIN ON TRACK TO START PHASE 3 CLINICAL TRIAL OF VERDIPERSTAT LATER THIS YEAR.  Full Article

Biohaven Announces Proposed Public Offering Of Common Shares
Tuesday, 11 Dec 2018 

Dec 10 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES.COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF 3 MILLION OF ITS COMMON SHARES.ALL OF COMMON SHARES TO BE SOLD IN OFFERING WILL BE OFFERED BY BIOHAVEN.  Full Article

Biohaven Pharmaceutical Holding Co Ltd files for offering of up to 3.0 million shares of common stock - SEC Filing
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD FILES FOR OFFERING OF UP TO 3.0 MILLION SHARES OF COMMON STOCK - SEC FILING.  Full Article

Biohaven Delivers Positive Phase 3 Results With Rimegepant For Treatment Of Migraine
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN DELIVERS POSITIVE PHASE 3 RESULTS WITH RIMEGEPANT ZYDIS® ORALLY DISSOLVING TABLET (ODT): RAPID AND LASTING BENEFIT FOR THE ACUTE TREATMENT OF MIGRAINE.BIOHAVEN - ACHIEVED STATISTICAL SIGNIFICANCE ON REGULATORY CO-PRIMARY ENDPOINTS OF PAIN FREEDOM & FREEDOM FROM MOST BOTHERSOME SYMPTOM AT 2 HOURS.BIOHAVEN- DIFFERENTIATED EFFICACY, SAFETY PROFILE WITH RIMEGEPANT IN ALL 3 PIVOTAL PHASE 3 TRIALS SUPPORT PLANNED NEW DRUG APPLICATION SUBMISSION IN H1 2019.  Full Article

Biohaven Announces FDA Acceptance Of 505(B) NDA Filing For BHV-0223
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NDA FILING FOR BHV-0223, A NOVEL SUBLINGUAL DELIVERY FORM OF RILUZOLE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS).  Full Article

Biohaven Pharmaceuticals Qtrly Loss Per Share $1.53
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL AND RECENT BUSINESS RESULTS.QTRLY NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS OF CO $1.53 PER SHARE.  Full Article

Biohaven restructures license agreement with Bristol-Myers Squibb to reduce royalties payable on its migraine product candidates
Monday, 12 Mar 2018 

March 12 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN RESTRUCTURES LICENSE AGREEMENT WITH BRISTOL-MYERS SQUIBB TO REDUCE ROYALTIES PAYABLE ON ITS MIGRAINE PRODUCT CANDIDATES; TRANSACTION FINANCED THROUGH PRIVATE PLACEMENT WITH LEADING INSTITUTIONAL INVESTORS.BIOHAVEN PHARMACEUTICAL-CO TO PAY BMS UPFRONT PAYMENT OF $50 MILLION IN RETURN FOR LOW SINGLE DIGIT REDUCTION IN ROYALTIES ON NET SALES OF RIMEGEPANT​.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY - ‍UPFRONT PAYMENT FOR RESTRUCTURING FINANCED THROUGH PRIVATE PLACEMENT OF CO COMMON SHARES TO INVESTORS​.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY - ‍BIOHAVEN'S OBLIGATIONS TO MAKE DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS TO BMS REMAIN UNCHANGED​.BIOHAVEN PHARMACEUTICAL HOLDING - ‍RESTRUCTURING OF AGREEMENT WITH BRISTOL-MYERS FOR SMALL MOLECULE CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST PLATFORM​.BIOHAVEN PHARMACEUTICAL HOLDING CO - CO WILL PAY BMS $50 MILLION IN RETURN FOR A MID-SINGLE DIGIT REDUCTION IN ROYALTIES PAYABLE ON NET SALES OF BHV-3500​.BIOHAVEN PHARMACEUTICAL-‍RESTRUCTURING WAS FINANCED THROUGH A $55 MILLION PRIVATE PLACEMENT OF 2 MILLION BIOHAVEN COMMON SHARES AT A PRICE OF $27.50 PER SHARE​.  Full Article

Biohaven Pharmaceutical Q4 Loss Per Share $0.75
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND BUSINESS RESULTS.Q4 LOSS PER SHARE $0.75.  Full Article